Wall Street brokerages expect Radius Health, Inc. (NASDAQ:RDUS) to announce ($0.23) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Radius Health’s earnings, with estimates ranging from ($0.26) to ($0.18). Radius Health posted earnings of ($0.14) per share during the same quarter last year, which would suggest a negative year over year growth rate of 64.3%. The firm is expected to report its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Radius Health will report full-year earnings of ($0.92) per share for the current year, with EPS estimates ranging from ($1.26) to ($0.65). For the next fiscal year, analysts forecast that the company will report earnings of $0.84 per share, with EPS estimates ranging from $0.56 to $1.06. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Radius Health.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $51.80 million for the quarter, compared to analysts’ expectations of $58.92 million.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada grew its position in Radius Health by 11.0% during the 1st quarter. Royal Bank of Canada now owns 5,434 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 538 shares during the period. Alps Advisors Inc. grew its position in shares of Radius Health by 1.0% during the 1st quarter. Alps Advisors Inc. now owns 84,838 shares of the biopharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 840 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Radius Health by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,027 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 885 shares during the period. Sei Investments Co. grew its position in shares of Radius Health by 4.3% during the 2nd quarter. Sei Investments Co. now owns 24,508 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 1,000 shares during the period. Finally, Virtus ETF Advisers LLC grew its position in shares of Radius Health by 2.8% during the 1st quarter. Virtus ETF Advisers LLC now owns 42,536 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 1,161 shares during the period.
Shares of NASDAQ RDUS traded up $0.06 during mid-day trading on Thursday, hitting $12.18. The stock had a trading volume of 317,317 shares, compared to its average volume of 382,251. The company has a 50 day moving average of $14.52 and a two-hundred day moving average of $18.25. Radius Health has a twelve month low of $10.15 and a twelve month high of $26.16. The firm has a market cap of $575.70 million, a PE ratio of -9.40 and a beta of 0.91.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.
Featured Article: Debt-To-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.